Overview


According to FutureWise analysis the market for vaccine combinations in 2023 is US$ 6.75 billion, and is expected to reach US$ 11.28 billion by 2031 at a CAGR of 6.6%.

Antigens that protect against multiple strains of infectious pathogens that cause the same disease are mixed in vaccine combinations. Antibody-antigen reactions are induced by vaccines, which contribute in the development of disease resistance. Vaccines include recombinant vaccines, conjugate vaccinations, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. This reduces the number of vaccinations required to keep some diseases in check. Combination vaccines for protection against many diseases were created by combining individual diphtheria, tetanus, and pertussis (DTP) shots into a single medication. Vaccines are products that act with the immune system of the body to build up protection against dangerous pathogens, lowering the risk of infection. The growth of the vaccine combinations market is expected to be influenced by the rising incidence of infectious illnesses. The rising awareness of the benefits of vaccination and immunisation in emerging regions is predicted to boost the market's growth pace. The focus on immunisation has moved dramatically as a result of increased healthcare knowledge, and a number of government institutions are attempting to attain this goal. Immunize Australia, for example, is an Australian government programme that assists people in purchasing vaccines. The National Immunization Program (NIP) Schedule is also in place, which now includes vaccines for 16 diseases, including diphtheria, measles, and whooping cough (pertussis), as well as vaccines that have just recently been identified, such as the meningococcal ACWY and HPV vaccines. Furthermore, the market's expansion is supported by an increase in the number of R D activities.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Vaccine Combinations Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Vaccine Combinations Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Bio Farma
  • Bharat Biotech
  • Serum Institute of India Pvt. Ltd.
  • Biological E Limited.
  • Novartis AG
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Johnson and Johnson Private Limited
  • Sanofi
  • MerckCo., Inc.
  • Baxter
  • Csl Limited
  • Abbott.
  • F. Hoffmann-La Roche Ltd.
  • Daiichi Sankyo Company, Limited
  • Emergent
  • Dynavax Technologies
  • Valneva SE
  • Bavarian Nordic A/S
  • Panacea Biotec
  • Mitsubishi Tanabe Pharma Corporation

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Adacel
  • Vaxelis
  • Twinrix
  • Quadracel
  • M-M-R II
  • Comvax
  • Others

By Application

  • Diphtheria Prophylaxis
  • Haemophilus influenzae Prophylaxis
  • Hepatitis A Prophylaxis
  • Hepatitis B Prevention
  • Mumps Prophylaxis
  • Measles Prophylaxis
  • Poliomyelitis Prophylaxis
  • Pertussis Prophylaxis
  • Rubella Prophylaxis
  • Tetanus Prophylaxis
  • Others

By Product Type

  • Two Combinations
  • Three Combinations
  • Four Combinations
  • Six Combinations

By Demographic

  • Adult
  • Pediatrics

By Type

  • Subunit
  • Recombinant
  • Polysaccharide and Conjugate Vaccines
  • Live-Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • DNA Vaccines

By Kind

  • Routine Vaccine
  • Recommended Vaccine
  • Required Vaccine

By Route of Administration

  • Injectable
  • Oral
  • Nasal

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Vaccine Combinations Market By Drug Type, By Application, By Product Type, By Demographic, By Type, By Kind, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Vaccine Combinations Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Vaccine Combinations Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Vaccine Combinations Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Vaccine Combinations Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Adacel
        2. Vaxelis
        3. Twinrix
        4. Quadracel
        5. M-M-R II
        6. Comvax
        7. Others

  • 8.   Vaccine Combinations Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diphtheria Prophylaxis
        2. Haemophilus influenzae Prophylaxis
        3. Hepatitis A Prophylaxis
        4. Hepatitis B Prevention
        5. Mumps Prophylaxis
        6. Measles Prophylaxis
        7. Poliomyelitis Prophylaxis
        8. Pertussis Prophylaxis
        9. Rubella Prophylaxis
        10. Tetanus Prophylaxis
        11. Others

  • 9.   Vaccine Combinations Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Two Combinations
        2. Three Combinations
        3. Four Combinations
        4. Six Combinations

  • 10.   Vaccine Combinations Market, By Demographic Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Adult
        2. Pediatrics

  • 11.   Vaccine Combinations Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Subunit
        2. Recombinant
        3. Polysaccharide and Conjugate Vaccines
        4. Live-Attenuated Vaccines
        5. Inactivated Vaccines
        6. Toxoid Vaccines
        7. DNA Vaccines

  • 12.   Vaccine Combinations Market, By Kind Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Routine Vaccine
        2. Recommended Vaccine
        3. Required Vaccine

  • 13.   Vaccine Combinations Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injectable
        2. Oral
        3. Nasal

  • 14.   Vaccine Combinations Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 15.   Vaccine Combinations Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 16.   North America Vaccine Combinations Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 17.   Latin America Vaccine Combinations Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 18.   Europe Vaccine Combinations Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 19.   Asia Pacific Vaccine Combinations Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 20.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 21.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 22.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Bio Farma
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Bharat Biotech
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Serum Institute of India Pvt. Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Biological E Limited.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. GlaxoSmithKline plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Takeda Pharmaceutical Company Limited
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Johnson & Johnson Private Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Sanofi
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. MerckCo., Inc.
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Baxter
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Csl Limited
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
         14. Abbott.
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
        15. F. Hoffmann-La Roche Ltd.
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Daiichi Sankyo Company, Limited
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Emergent
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. Dynavax Technologies
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. Valneva SE
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
         20. Bavarian Nordic A/S
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview
         21. Panacea Biotec
          21.1. Company Overview
          21.2. Product Portfolio
          21.3. SWOT Analysis
          21.4. Financial Overview
          21.5. Strategic Overview
          22. Mitsubishi Tanabe Pharma Corporation
          22.1. Company Overview
          22.2. Product Portfolio
          22.3. SWOT Analysis
          22.4. Financial Overview
          22.5. Strategic Overview

  • 23.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 24.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients